Stockscreener 앱 받기
88.40
0.26%
-0.42
전일 마감가:
$88.82
열려 있는:
$88.2
하루 거래량:
5.51M
Relative Volume:
0.47
시가총액:
$154.02B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
24.63
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+5.67%
1개월 성능:
-7.72%
6개월 성능:
-28.54%
1년 성능:
-34.48%
1일 변동 폭
$87.10
$88.78
1주일 범위
$84.05
$89.34
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
88.42 | 153.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
320.82 | 120.08B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.90 | 99.27B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.62 | 83.12B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.78 | 47.44B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum - TradingView
Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly updat - AD HOC NEWS
Worker says Abbott fired him over a chat his coworker started - hcamag.com
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit - AboutLawsuits.com
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu - AD HOC NEWS
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity? - simplywall.st
Build-A-Bear Workshop and Abbott Laboratories o... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review - Traders Union
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Stock Analysis: Unlocking a 40% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc. - MarketBeat
Abbott Laboratories stock (US0028241000): Q1 2026 growth, guidance raise and diabetes momentum - AD HOC NEWS
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused - AD HOC NEWS
Abbott Laboratories Stock (ABT) Opinions on Recent Price Declines - Quiver Quantitative
Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly u - AD HOC NEWS
Abbott Laboratories $ABT Stock Holdings Lowered by iA Global Asset Management Inc. - MarketBeat
AlphaCore Capital LLC Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Abacus Wealth Partners LLC Buys 12,260 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Trade Ideas — LSX:850103 - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Nutrition Setbacks Legal Uncertainty And Softer Analyst Sentiment - simplywall.st
Commerzbank Aktiengesellschaft FI Sells 131,572 Shares of Abbott Laboratories $ABT - MarketBeat
Bessemer Group Inc. Sells 213,665 Shares of Abbott Laboratories $ABT - MarketBeat
ABT (NYSE: ABT) Form 144 shows 7,587 RSU shares and prior 29,211 sale - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Is the options market predicting a spike in Abbott Laboratories stock? - MSN
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Phoenix Financial Ltd. Increases Stock Position in Abbott Laboratories $ABT - MarketBeat
Summit Wealth Group LLC Co. Sells 21,449 Shares of Abbott Laboratories $ABT - MarketBeat
Conning Inc. Grows Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) Short Interest & Short Float | Updated May 2026 $ABT - MarketBeat
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
ABT Stock Quote Price and Forecast - CNN
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
0.86%
자본화:
|
볼륨(24시간):